Form 4: Sage Therapeutics Executive Gregory Shiferman Reports Stock Transaction
SEC Form 4 Filing
Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On February 24, 2025, Gregory Shiferman, Senior Vice President, General Counsel and Secretary at Sage Therapeutics, had shares withheld to cover tax obligations.
- This transaction occurred due to the vesting of 7,500 time-based restricted stock units (RSUs) granted on August 24, 2023, under the company's 2014 Stock Option and Incentive Plan.
- A total of 2,502 shares were withheld at a price of $7.49 per share.
- Following the transaction, Shiferman directly owns 30,759 shares of Sage Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment.
Industry Context
This is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine tax-related withholding.
Key Dates
| Date | Description |
|---|---|
| 2023-08-24 | Date of grant for the time-based restricted stock units (RSUs). |
| 2024-11-01 | Date of Power of Attorney document. |
| 2025-02-24 | Date of the stock transaction (withholding of shares for tax obligations). |
| 2025-02-25 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.